Media stories about Alpine Immune Sciences (NASDAQ:ALPN) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alpine Immune Sciences earned a coverage optimism score of 0.03 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.2088007727231 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of brokerages have commented on ALPN. ValuEngine raised Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a research report on Friday, June 1st. Zacks Investment Research cut Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Monday, May 21st. Wedbush initiated coverage on Alpine Immune Sciences in a research report on Thursday, May 17th. They set an “outperform” rating and a $13.00 price target for the company. Citigroup initiated coverage on Alpine Immune Sciences in a report on Thursday, June 28th. They issued an “outperform” rating and a $13.00 price objective for the company. Finally, Oppenheimer initiated coverage on Alpine Immune Sciences in a report on Friday, June 29th. They issued an “outperform” rating and a $13.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $12.75.
Shares of Alpine Immune Sciences traded up $0.06, hitting $7.00, on Thursday, MarketBeat.com reports. The company had a trading volume of 15,500 shares, compared to its average volume of 18,218. The stock has a market cap of $96.58 million, a PE ratio of -5.83 and a beta of 0.55. The company has a quick ratio of 26.71, a current ratio of 26.70 and a debt-to-equity ratio of 0.05. Alpine Immune Sciences has a twelve month low of $6.77 and a twelve month high of $12.87.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
See Also: Should you buy a closed-end mutual fund?
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.